Incannex Healthcare Ltd ADR (NASDAQ:IXHL) — Market Cap & Net Worth
Market Cap & Net Worth: Incannex Healthcare Ltd ADR (IXHL)
Incannex Healthcare Ltd ADR (NASDAQ:IXHL) has a market capitalization of $38.01 Million ($38.01 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23024 globally and #5039 in its home market, demonstrating a 4.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Incannex Healthcare Ltd ADR's stock price $3.79 by its total outstanding shares 13973663 (13.97 Million). Also see Incannex Healthcare Ltd ADR assets under control for a full breakdown of the balance sheet.
Incannex Healthcare Ltd ADR Market Cap History: 2022 to 2026
Incannex Healthcare Ltd ADR's market capitalization history from 2022 to 2026. Data shows change from $39.13 Million to $45.97 Million (-28.10% CAGR). Also see cash efficiency ratio of Incannex Healthcare Ltd ADR for how efficiently the company converts equity into cash flow.
Index Memberships
Incannex Healthcare Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #656 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #2169 of 3165 |
Weight: Incannex Healthcare Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Incannex Healthcare Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Incannex Healthcare Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Incannex Healthcare Ltd ADR stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
58.17x
Incannex Healthcare Ltd ADR's market cap is 58.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $39.13 Million | $785.15K | -$14.90 Million | 49.83x | N/A |
| 2023 | $64.84 Million | $1.01 Million | -$73.47 Million | 63.95x | N/A |
| 2024 | $29.62 Million | $12.00K | -$18.46 Million | 2468.68x | N/A |
| 2025 | $5.00 Million | $86.00K | -$46.88 Million | 58.17x | N/A |
Competitor Companies of IXHL by Market Capitalization
Companies near Incannex Healthcare Ltd ADR in the global market cap rankings as of September 17, 2026. Review Incannex Healthcare Ltd ADR (IXHL) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Incannex Healthcare Ltd ADR by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Incannex Healthcare Ltd ADR Historical Marketcap From 2022 to 2026
Between 2022 and today, Incannex Healthcare Ltd ADR's market cap moved from $39.13 Million to $ 45.97 Million, with a yearly change of -28.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $45.97 Million | +818.99% |
| 2025 | $5.00 Million | -83.11% |
| 2024 | $29.62 Million | -54.31% |
| 2023 | $64.84 Million | +65.71% |
| 2022 | $39.13 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Incannex Healthcare Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.01 Million USD |
| MoneyControl | $38.01 Million USD |
| MarketWatch | $38.01 Million USD |
| marketcap.company | $38.01 Million USD |
| Reuters | $38.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more